title: Chemotherapy for metastatic castrate-sensitive prostate cancer.
abstract: The role of docetaxel chemotherapy in combination with androgen deprivation therapy for metastatic castrate-sensitive prostate cancer is emerging.
  
  
  
  We reviewed the results from the pivotal randomized phase III trials in this area: GETUG15, CHAARTED and STAMPEDE.
  
  
  
  All three studies demonstrated a benefit in progression-free survival with the use of docetaxel. However, two of the studies demonstrated a clinically meaningful overall survival benefit (CHAARTED and STAMPEDE), whereas the GETUG15 study did not demonstrate a major benefit.
  
  
  
  Docetaxel is an important option to consider for men who are fit for chemotherapy with newly diagnosed metastatic prostate cancer commencing androgen deprivation therapy.
authors.affiliation: Department of Medical Oncology, University College London Hospital, London, UK.
authors.forename: R E
authors.initials: RE
authors.lastname: Miller
authors.affiliation: Department of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: C J
authors.initials: CJ
authors.lastname: Sweeney
mesh_terms: D000726:Androgen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D000077143:Docetaxel; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D016032:Randomized Controlled Trials as Topic; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D043823:Taxoids; D000077143:Docetaxel